Older Adults on Prescribed Cannabis Report Well-Being Gains, But Study Cannot Rule Out Placebo or Natural Recovery

UK registry data show older patients differ markedly from younger users in diagnosis, product choice, and prior cannabis use, but the uncontrolled observational design and substantial loss to follow-up prevent any causal conclusions about whether the medications drove the reported improvements.

Why This Matters

Adults over 65 represent the fastest-growing segment of interest in medical cannabis, yet they remain the least studied. This population carries a disproportionate burden of chronic pain, polypharmacy, and drug interaction risk, making evidence-based prescribing guidance especially urgent. At the same time, UK private-sector cannabis clinics are actively enrolling older patients, and the gap between commercial access and rigorous evidence continues to widen. Understanding who these patients are and what they are being prescribed is a necessary first step, even when the outcome data cannot yet tell us whether the treatments work.

Clinical Summary

Chronic pain affects the majority of older adults seeking prescribed cannabis in the United Kingdom, yet until recently almost no data existed describing this population’s characteristics, prescribing patterns, or short-term outcomes. Sheridan and colleagues, publishing in Expert Review of Neurotherapeutics in 2024, used the T21 registry, a prospective multi-centre patient registry drawn from private telemedicine cannabis clinics, to compare adults aged 65 and older with younger patients on demographics, diagnoses, prior cannabis experience, products prescribed, and self-reported well-being at baseline and three months. The rationale for examining older adults specifically rests on their distinct pharmacological profile: age-related changes in hepatic metabolism, increased receptor sensitivity, greater polypharmacy exposure, and a higher prevalence of conditions such as chronic pain and insomnia that overlap with proposed cannabinoid mechanisms of action.

The descriptive findings are the study’s most reliable contribution. Among 198 older adults at baseline, 76% cited pain as their primary condition compared with 46% of younger patients. Older adults were far less likely to be current daily cannabis users (20% versus 60%) and received fewer products on average, with a greater share prescribed CBD-dominant oils rather than THC-dominant flower. Self-reported quality of life, general health, mood, and sleep all improved significantly in both age groups over three months, though sleep gains were larger in younger patients. However, the absence of a control group means these improvements could reflect placebo response, regression to the mean, natural symptom fluctuation, or concurrent treatments. Loss to follow-up was substantial, with only 98 older adults (49.5%) completing the three-month assessment, raising serious concerns about attrition bias. The authors acknowledge that randomised controlled trials are needed before clinical recommendations can be made.

Dr. Caplan’s Take

The descriptive work here is genuinely useful. Knowing that older adults prescribed cannabis in UK clinics are predominantly pain patients with limited prior cannabis experience and that they tend to receive CBD-dominant products rather than high-THC flower gives us a clearer picture of real-world practice. That picture matters because patients in this age group frequently ask whether medical cannabis might help their chronic pain, and they deserve an honest answer rooted in what we actually know rather than what we hope might be true. Right now, the outcome data from this study cannot tell us whether the treatments caused improvement.

In practice, when an older patient asks about medical cannabis for pain, I start with what the evidence does support: optimizing existing analgesic strategies, addressing sleep and mood comorbidities directly, and being transparent that current cannabis outcome data in this age group comes from uncontrolled registries rather than trials. If a patient is already using or determined to try cannabis, the clinical priority shifts to harm reduction: starting low, preferring CBD-dominant formulations, reviewing drug interactions carefully, and monitoring falls risk and cognitive function at every follow-up.

Clinical Perspective

This study sits early in the research arc for geriatric cannabinoid therapeutics, contributing descriptive epidemiology rather than efficacy evidence. It confirms what smaller case series have suggested: that older adults entering medical cannabis programs present with different clinical profiles and receive different products than younger patients. What it cannot resolve, and what remains the central unanswered question, is whether prescribed cannabinoids produce clinically meaningful benefit in this population beyond what would occur with placebo, time, or standard care. Until randomised controlled data exist, clinicians should not cite registry improvements as evidence of treatment efficacy when counseling patients.

From a pharmacological standpoint, the older adult population carries specific risks that this study does not address in depth. THC interacts with CYP3A4 and CYP2C9 substrates, which include warfarin, certain statins, and many antihypertensives commonly used in this age group. CBD is a potent CYP3A4 inhibitor and can elevate levels of benzodiazepines, opioids, and immunosuppressants. Falls risk and cognitive side effects are also amplified in older adults. Clinicians who encounter patients already using prescribed cannabis should conduct a thorough medication interaction review at each visit and document any dose adjustments to concurrent medications prompted by cannabinoid co-administration.

Study at a Glance

Study Type

Prospective observational registry study with pre-post design and age-stratified comparison

Population

Adults prescribed cannabis-based medicinal products through UK private telemedicine clinics (4,228 total; 198 aged 65+)

Intervention

Cannabis-based medicinal products including CBD-dominant oils, THC-dominant flower, and balanced formulations

Comparator

None (within-subject pre-post comparison only; no placebo or usual-care control group)

Primary Outcomes

Quality of life (EQ-5D-5L), general health (VAS), mood (PHQ-9), sleep quality (Pittsburgh Sleep Quality Index items)

Sample Size

4,228 at baseline; 2,342 at 3-month follow-up (98 older adults at follow-up)

Journal

Expert Review of Neurotherapeutics

Year

2024

DOI or PMID

See references for full citation details

Funding Source

All authors affiliated with Drug Science, which operates the T21 registry and partners with cannabis producers

What Kind of Evidence Is This

This is an original prospective observational study using registry data in a pre-post design without a control group. It sits in the lower tiers of the evidence hierarchy, above case reports but well below randomised controlled trials or systematic reviews. The single most important inference constraint is the absence of any comparator arm: without knowing what would have happened to similar patients who did not receive cannabis-based products, no observed improvement can be attributed to the intervention rather than to placebo response, regression to the mean, natural disease fluctuation, or concurrent treatments.

How This Fits With the Broader Literature

The descriptive findings align with international data from Canadian and Israeli medical cannabis registries showing that older adults enter these programs primarily for chronic pain and receive more conservative prescribing. A 2020 Israeli prospective study by Abuhasira and colleagues similarly found that older adults reported improvements in pain and quality of life after six months of medical cannabis, but that study also lacked a control group and experienced significant attrition. The current study extends this pattern to the UK private-sector context and adds granularity on product type and prior use history. However, neither this study nor any existing registry study resolves the fundamental question of efficacy, which remains unanswered in the absence of adequately powered randomised controlled trials in this age group.

Common Misreadings

The most likely overinterpretation is reading the reported improvements in quality of life, mood, and sleep as evidence that medical cannabis works for older adults. This exceeds what an uncontrolled pre-post design can demonstrate. Patients who enroll in private cannabis clinics, pay out of pocket, and complete follow-up questionnaires are a self-selected group with high treatment expectations, and expectation alone can drive substantial improvements on self-report measures. The 51% attrition rate further compounds this problem: if patients who stopped treatment or experienced poor outcomes were less likely to complete follow-up, the remaining sample overestimates benefit. The descriptive findings about patient characteristics and prescribing patterns are more robust and should be cited separately from the outcome data.

Bottom Line

This study provides a useful descriptive portrait of older adults entering UK medical cannabis programs, confirming that they differ meaningfully from younger patients in diagnosis, prior use, and products prescribed. The self-reported well-being improvements, while plausible, cannot be attributed to the intervention given the absence of a control group, high attrition, and small older-adult sample. Clinicians should treat the outcome data as hypothesis-generating rather than practice-changing and await randomised controlled evidence before incorporating these findings into prescribing decisions for older patients.

References

1. Sheridan A, et al. Cannabis-based medicinal products for older adults: patient characteristics, prescribing patterns, and self-reported outcomes from the UK T21 registry. Expert Review of Neurotherapeutics. 2024.
2. Abuhasira R, Schleider LB, Mechoulam R, Novack V. Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly. European Journal of Internal Medicine. 2018;49:44-50.